Articles dans des revues avec comité de lecture (173)
145.
Martin, P., Schoutens, A., Manicourt, D., Bergmann, P., Fuss, M., & Verbanck, M. (1983). Whole body and regional retention of99mTc-labeled pyrophosphate at 24 hours: Physiological basis of the method for assessing the metabolism of bone in disease. Calcified tissue international, 35(1), 37-42. doi:10.1007/BF02405004148.
Fuss, M., Gillet, C., Simon, J., Vandewalle, J. C., Schoutens, A., & Bergmann, P. (1983). Bone mineral content in idiopathic renal stone disease and in primary hyperparathyroidism. European Urology, 9, 32-34.150.
Fuss, M., Bergmann, P., Verbanck-Taverne, J., Verbeelen, D., & Vanherweghem, J.-L. (1982). Unexplained hypercalcemia in maintenance hemodialysis: control by small dosages of prednisolone. Archives of Internal Medicine, 142(5), 1041-1042.153.
Vanherweghem, J.-L., D'haene, M., Tielemans, C., Dratwa, M., Verbanck, P., Bergmann, P., Schoutens, A., & Fuss, M. (1981). Predictive value of 99m Tc pyrophosphate bone scintigraphy for vitamin D trials in uraemia. Proceedings of the European Dialysis and Transplant Association, 18, 648-651.154.
Bergmann, P., Hall, M., Janssen, F., & Fuss, M. (1981). Bone mineral content (BMC) in hemodialyzed children: Effect of 1,25 dihydroxycholecalciferol (1,25 OH D3). Calcified tissue international, 33(Suppl), No. 149.